AIM ImmunoTech is trading at $0.23 (-6.76%) following a weak start to the session, likely driven by broader risk-off pressure in the biotech and small-cap space.
- The decline appears tied to sector-wide sentiment rather than company-specific news, as no fresh earnings, FDA updates, or financing events were reported for the July 28 session.
- The biotech sector is down 2.16% on general market weakness, with AIM ImmunoTech experiencing a sharper intraday drop characteristic of thin-cap volatility.